Allarity Therapeutics vs Quantum Cyber
ALLR and QUCY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALLR and QUCY compare
Quantum Cyber scores higher on the StockData Score (3 against 1 for Allarity Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALLR | QUCY |
|---|---|---|
| Size and price | ||
| Market cap | $13.9M | – |
| Share price | $0.875 | $0.630 |
| Change, 1 year | −26.5% | −53.7% |
| Change, 5 years | – | −93.6% |
| Beta (5Y) | 1.41 | – |
| Employees | 8 | 3 |
| StockData Score | ||
| Total score | 1 | 3 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.9× | – |
| Growth | ||
| Revenue growth (TTM) | – | −39.9% |
| Revenue growth, 5Y average | – | 1.7% |
| Profitability | ||
| Gross margin | – | 72.6% |
| Operating margin | – | −3005% |
| Net margin | – | −3018% |
| FCF margin | – | −2045% |
| Return on equity | −157% | −141% (better) |
| Return on invested capital | −957% | −324% (better) |
| Financial health | ||
| Debt / equity | 5.90 | – |
| Interest coverage | −10.1× (better) | −43.2× |
| Current ratio | 1.11 | 5.56 (better) |
| Altman Z-score | −6.64 | – |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 6.4% | – |
| Shareholder yield | 6.4% | – |
| Ownership | ||
| Held by institutions | 8.1% | 2.4% |
| Held by insiders | 6.3% | – |
| Insider net buying, 12 months | – | $0 |
| Short interest, % of float | 1.5% | – |
Go deeper
- ALLR stock overview
- ALLR income statement
- ALLR valuation and score
- QUCY stock overview
- QUCY income statement
- QUCY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.